The research conducted by Samuel O. Antwi, Ph.D., is focused on the molecular, genetic and epigenetic factors that contribute to the development of hepatocellular carcinoma (the most common form of primary liver cancer) and pancreatic cancer.
Dr. Antwi's research involves integrating rigorous epidemiological methods with clinical and high-throughput genomic data to elucidate the molecular processes that underlie cancer susceptibility. A keen focus of this research is on analyzing and interpreting data in a biologically meaningful way, with the intent that it be used for practical actions that will benefit patients and populations.
- Genetic and epigenetic factors associated with hepatocellular carcinoma development. Dr. Antwi's research involves investigation of the roles of inherited genetic variability and acquired epigenetic modification to DNA in hepatocellular carcinoma development. Specifically, he is testing the hypotheses that inherited genetic variants, acquired modifications to DNA and metabolic molecules that are produced through the one-carbon metabolism pathway either act independently or in concert to influence hepatocellular carcinoma development in people with nonalcoholic fatty liver disease. The findings from this research are expected to improve cancer risk assessment and stratification, and early detection of hepatocellular carcinoma.
- Genetic, molecular and nongenetic risk factors for pancreatic cancer. Dr. Antwi utilizes candidate gene and pathway-based approaches to study the roles of genetic variants in susceptibility to pancreatic cancer. He also studies how molecular factors (such as telomere length) interact with telomere maintenance genes to influence pancreatic cancer risk. Part of his research involves evaluation of the role of lifestyle factors such as obesity, cigarette smoking and inflammatory potential of diet in pancreatic cancer development.
Significance to patient care
The goal of Dr. Antwi's research is to improve strategies for risk prevention, early detection and timely clinical intervention for patients with pancreatic and liver cancers.
- Associate council member, Cohort Consortium, National Cancer Institute (NCI), 2019-present
- Member, Hepatocellular Carcinoma Epidemiology Consortium, NCI, 2017-present
- Member, Pancreatic Cancer Case-Control Consortium, NCI, 2015-present
- Member, Molecular Epidemiology Working Group, American Association for Cancer Research, 2015-present
- Reviewer, Cancer Research; JNCI Cancer Spectrum; Cancer Epidemiology, Biomarkers & Prevention; American Journal of Epidemiology; International Journal of Epidemiology; Hepatology; Molecular Carcinogenesis; and others